IL123805A - Pharmaceutical components containing derivatives of hydroxymic acid to protect the mitochondrial genome and / or mitochondria from damage or to treat diseases related to these damages - Google Patents

Pharmaceutical components containing derivatives of hydroxymic acid to protect the mitochondrial genome and / or mitochondria from damage or to treat diseases related to these damages

Info

Publication number
IL123805A
IL123805A IL12380596A IL12380596A IL123805A IL 123805 A IL123805 A IL 123805A IL 12380596 A IL12380596 A IL 12380596A IL 12380596 A IL12380596 A IL 12380596A IL 123805 A IL123805 A IL 123805A
Authority
IL
Israel
Prior art keywords
formula
compound
group
acid addition
pharmaceutically acceptable
Prior art date
Application number
IL12380596A
Other languages
English (en)
Hebrew (he)
Other versions
IL123805A0 (en
Inventor
Peter Literati Nagy
Balazs Sumegi
Laszlo Vigh
Bruno Maresca
Original Assignee
Medgene Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medgene Ltd filed Critical Medgene Ltd
Publication of IL123805A0 publication Critical patent/IL123805A0/xx
Publication of IL123805A publication Critical patent/IL123805A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/539—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more oxygen atoms in the same ring, e.g. dioxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
IL12380596A 1995-09-29 1996-09-26 Pharmaceutical components containing derivatives of hydroxymic acid to protect the mitochondrial genome and / or mitochondria from damage or to treat diseases related to these damages IL123805A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU9502843A HU9502843D0 (en) 1995-09-29 1995-09-29 Pharmaceutical composition
PCT/HU1996/000053 WO1997013504A1 (fr) 1995-09-29 1996-09-26 Compositions pharmaceutiques contenant des derives d'acide hydroximique

Publications (2)

Publication Number Publication Date
IL123805A0 IL123805A0 (en) 1998-10-30
IL123805A true IL123805A (en) 2001-10-31

Family

ID=10987259

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12380596A IL123805A (en) 1995-09-29 1996-09-26 Pharmaceutical components containing derivatives of hydroxymic acid to protect the mitochondrial genome and / or mitochondria from damage or to treat diseases related to these damages

Country Status (14)

Country Link
US (1) US6306878B1 (fr)
EP (2) EP0852495B1 (fr)
JP (2) JP3932559B2 (fr)
KR (1) KR100363069B1 (fr)
CN (2) CN1104894C (fr)
AT (1) ATE321543T1 (fr)
AU (1) AU7092296A (fr)
CA (1) CA2233315C (fr)
DE (1) DE69635996T2 (fr)
HU (1) HU9502843D0 (fr)
IL (1) IL123805A (fr)
RU (1) RU2191005C2 (fr)
UA (1) UA57712C2 (fr)
WO (1) WO1997013504A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU222994B1 (hu) * 1995-11-02 2004-01-28 BIOREX Kutató és Fejlesztő Rt. Hidroxilaminszármazékok és azok alkalmazása sejtek molekuláris chaperon-termelésének fokozására alkalmas gyógyszerkészítmények előállítására
HU9701081D0 (en) 1997-06-23 1997-08-28 Gene Research Lab Inc N Pharmaceutical composition of antitumoral activity
HUP9701080A3 (en) 1997-06-23 1999-05-28 Gene Res Lab Inc New York N Pharmaceutical composition containing a compound of antiviral activity and a hydroximic acid ester derivative
CA2319131A1 (fr) * 1998-01-26 1999-07-29 Walter H. Moos Agents protegeant les mitochondries et utilises dans le traitement des maladies associees aux mitochondries
AU3965699A (en) * 1998-04-24 1999-11-16 Mitokor Compounds and methods for treating mitochondria-associated diseases
AU5296799A (en) * 1998-08-03 2000-02-28 N-Gene Kutato Kft. Pharmaceutical compositions against autoimmune diseases
HUP0001583A2 (hu) 2000-04-18 2002-11-28 BIOREX Kutató és Fejlesztő Rt. Egy piridin-1-oxid-származék és eljárás annak átalakítására gyógyászati hatású vegyületekké
HU228783B1 (en) * 2001-07-26 2013-05-28 Greenearth Cleaning Dry cleaning apparatus and method capable of utilizing a siloxane solvent
KR20040089102A (ko) 2002-01-11 2004-10-20 비오렉스 쿠타토 에쉬 훼레스테 에르테 카르복사미딘 유도체 및 혈관 질환의 치료에서의 이들 용도
PL1663197T3 (pl) 2003-09-09 2008-09-30 Biogen Idec Int Gmbh Zastosowanie pochodnych kwasu fumarowego do leczenia niewydolności serca oraz astmy
HUP0303584A3 (en) * 2003-10-30 2009-12-28 Cytrx Corp Use of a hydroximic acid halide derivative in the treatment of neurodegenerative diseases
HUP0401177A2 (en) * 2004-06-14 2007-09-28 N Gene Res Lab Inc Pharmaceutical composition for increasing the mitochondrial genesis
HUP0500145A2 (en) * 2005-01-28 2006-11-28 Gene Res Lab N Use of o-(3-piperidino-2-hydroxy-1-propyl)-nicotinic amidoxime for preparation of medicaments against oral diseases
US20080108602A1 (en) * 2006-11-02 2008-05-08 N-Gene Research Laboratories, Inc. Prevention of obesity in antipsychotic, antidepressant and antiepileptic medication
US7763601B2 (en) * 2006-11-02 2010-07-27 N-Gene Research Laboratories, Inc. Prevention and treatment of obesity
EP4137819A1 (fr) 2007-02-08 2023-02-22 Biogen MA Inc. Compositions et leurs utilisations pour le traitement de la sclérose en plaques
US20090281143A1 (en) * 2007-12-10 2009-11-12 N-Gene Research Laboratories, Inc. Dose Reduction of a Cannabinoid CB1 Receptor Antagonist in the Treatment of Overweight or Obesity
HUP1100444A2 (en) 2011-08-17 2013-02-28 Pharma Gene Sa Pharmaceutical composition
HUP1100445A2 (en) * 2011-08-17 2013-02-28 Pharma Gene Sa Pharmaceutical composition
CN102408411B (zh) * 2011-09-19 2014-10-22 北京康辰药业股份有限公司 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
EP3263104A1 (fr) * 2016-07-01 2018-01-03 N-Gene Research Laboratories Inc. Utilisation de bgp15 pour stimuler la fusion mitochondriale
EP3263105A1 (fr) 2016-07-01 2018-01-03 Montana State University Utilisation de bgp15 pour traiter la dysautonomie familiale
EP3634411B1 (fr) 2017-06-08 2023-09-20 N-Gene Research Laboratories Inc. Méthodes de traitement de la stéatohépatite non alcoolique et de prévention d'un carcinome hépatocellulaire induit par la stéatohépatite non alcoolique
HUP1800298A1 (hu) 2018-08-30 2020-05-28 N Gene Res Laboratories Inc Gyógyszerkombináció béta-receptor blokkolók hatásának módosítására és a mellékhatások csökkentésére
IL303026A (en) 2020-11-19 2023-07-01 Zevra Denmark As Processes for preparing arimoclomol citrate and its intermediates

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4308399A (en) * 1977-08-30 1981-12-29 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. O-(3-Amino-2-hydroxy-propyl)-amidoxime derivatives, process for the preparation thereof and pharmaceutical compositions containing same
HU207988B (en) * 1988-10-20 1993-07-28 Biorex Kutato Fejlesztoe Kft Process for producing halogenides of o-/3-amino-2-hydroxy-propyl/hydroximic acid and pharmaceutical compositions containing them as active components
ES2123252T3 (es) * 1994-05-06 1999-01-01 Biorex Kutato Fejlesztoe Kft Nuevos derivados de acido hidroximico, composiciones farmaceuticas que los contienen y procedimiento para su preparacion.

Also Published As

Publication number Publication date
CN1263763A (zh) 2000-08-23
CN1200670A (zh) 1998-12-02
CA2233315A1 (fr) 1997-04-17
CN1104894C (zh) 2003-04-09
RU2191005C2 (ru) 2002-10-20
WO1997013504A1 (fr) 1997-04-17
DE69635996T2 (de) 2007-03-15
KR100363069B1 (ko) 2003-01-29
JP3932559B2 (ja) 2007-06-20
EP0852495A1 (fr) 1998-07-15
KR19990063907A (ko) 1999-07-26
EP0852495B1 (fr) 2006-03-29
DE69635996D1 (de) 2006-05-18
HU9502843D0 (en) 1995-11-28
EP1020187A1 (fr) 2000-07-19
IL123805A0 (en) 1998-10-30
JP2000302676A (ja) 2000-10-31
CA2233315C (fr) 2007-12-04
US6306878B1 (en) 2001-10-23
AU7092296A (en) 1997-04-30
ATE321543T1 (de) 2006-04-15
UA57712C2 (uk) 2003-07-15
JP2001519756A (ja) 2001-10-23

Similar Documents

Publication Publication Date Title
CA2233315C (fr) Compositions pharmaceutiques contenant des derives d&#39;acide hydroximique
Christophe et al. Mitochondria: a target for neuroprotective interventions in cerebral ischemia-reperfusion
US6127356A (en) Oxidant scavengers
CN103764147B (zh) 用于治疗的丙酮酸激酶活化剂
US20120225915A1 (en) Compositions and Methods of Using R(+) Pramipexole
JP5479455B2 (ja) ニトロン化合物、その製造方法およびその医薬用途
US20040116495A1 (en) Compounds and methods
NO319454B1 (no) Farmasoytiske preparater basert pa syntetiske katalytiske fri-radikal-oppfangere anvendelige som anti-oksidanter for forebyggelse og terapi av sykdom
EP2186512A1 (fr) Utilisation d&#39;allylcystéine ou de ses analogues et composition pharmaceutique
CA2756864A1 (fr) Agent prophylactique ou therapeutique des retinopathies comprenant un peptide inhibiteur de jnk (c-jun n-terminal kinase), methode de prevention ou de traitement des retinopathies, et utilisation du peptide
US7449482B2 (en) Piperidine compounds useful as malonyl-CoA decarboxylase inhibitors
TW425284B (en) A composition for treating and protecting a disorder in an organ or a tissue consisting phenylthiazole derivative
EP2400843B1 (fr) Iminosucres et procédés de traitement d&#39;infections arénavirales
EP0966283B1 (fr) Produits pharmaceutiques preventifs et curatifs de maladies resultant de degradations des cellules de l&#39;endothelium vasculaire
Paradies et al. Cardiolipin alterations and mitochondrial dysfunction in heart ischemia/reperfusion injury
CN109535072B (zh) 一种乙酰胆碱酯酶抑制剂及其应用
CA2288415A1 (fr) Compositions pharmaceutiques contenant des derives d&#39;acide hydroximique
EP2208495B1 (fr) Composes azole a base de cyanoguanidine-utilises comme inhibiteurs de malonyl-coa decarboxylase
JP4491229B2 (ja) ミトコンドリアを保護するための医薬を調製するためのチアゾール誘導体の使用
WO2024008788A1 (fr) Utilisation de l&#39;ebselen ou l&#39;un de ses derives pour traiter des pathologies ou dysfonctionnements des mitochondries
AU2008295145B2 (en) Use of urate oxidase for the treatment or prophylaxis of disorders or indirect sequelae of the heart caused by ischemic or reperfusion events
Ussipbek et al. Prospects of the application of coenzyme Q10 for correction of mitochondrial dysfunction
Horvath et al. Experimental therapy for mitochondrial diseases
JPH0667844B2 (ja) 虚血性心疾患の治療・予防剤
JPH10120569A (ja) 眼疾患予防または治療剤

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees